Literature DB >> 15193992

Peptidase activities in rats treated chronically with N(omega)-nitro-L-arginine methyl ester (L-NAME).

Alessandra Linardi1, Patricia Costa Panunto, Emer Suavinho Ferro, Stephen Hyslop.   

Abstract

The chronic treatment of rats with N(omega)-nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide (NO) biosynthesis, results in hypertension. This inhibition of NO production results in activation of the renin-angiotensin system, with increased activity of the carboxypeptidase angiotensin I-converting enzyme (ACE). Since chronic NO inhibition increases ACE activity, we hypothesized that this inhibition could also affect the activities of other peptidases involved in cardiovascular functions. To test this possibility, we examined the activities of aminopeptidase M (APM), dipeptidyl peptidase IV (DPP IV), metalloendopeptidase 24.15 (MEP 24.15) and neutral endopeptidase 24.11 (NEP 24.11) in rat brain, heart, kidney, liver, lung and thoracic aorta. Male Wistar rats were treated chronically with L-NAME (80mgkg(-1) per day) administered in the drinking water for 4 weeks and their organs then removed and processed for the determination of peptidase activities. Treatment with L-NAME did not significantly alter the activities of the four peptidases in brain, heart, kidney, liver and lung. In contrast, in aorta, the activity of APM was slightly but significantly reduced whereas those of DPP IV and MEP 24.15 were markedly enhanced; NEP 24.11 was not detected in this tissue. Immunoblotting for DPP IV and MEP 24.15 showed increased expression in aortic tissue. Neither L-NAME (1-100microM) nor the NO donors sodium nitroprusside and 3-morpholinosydnonimine (SIN-1; 1-100microM) had any consistent effect on the activity of recombinant MEP 24.15 or renal DPP IV. The importance of MEP 24.15 in peptide metabolism was confirmed in pentobartibal-anesthetized rats pretreated with the MEP 24.15 inhibitor N-[1-(R,S)-carboxy-3-phenylpropyl]-Ala-Aib-Tyr-p-aminobenzoate (JA2), which significantly potentiated the hypotensive response to bradykinin. The altered peptidase activities seen in aorta may contribute to modulating vascular responses in this model of hypertension.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15193992     DOI: 10.1016/j.bcp.2004.03.016

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  4 in total

Review 1.  Biological Context Linking Hypertension and Higher Risk for COVID-19 Severity.

Authors:  Caio A M Tavares; Matthew A Bailey; Adriana C C Girardi
Journal:  Front Physiol       Date:  2020-11-19       Impact factor: 4.566

2.  Characterization of thimet oligopeptidase and neurolysin activities in B16F10-Nex2 tumor cells and their involvement in angiogenesis and tumor growth.

Authors:  Thaysa Paschoalin; Adriana K Carmona; Elaine G Rodrigues; Vitor Oliveira; Hugo P Monteiro; Maria A Juliano; Luiz Juliano; Luiz R Travassos
Journal:  Mol Cancer       Date:  2007-07-09       Impact factor: 27.401

Review 3.  Aminopeptidases in Cardiovascular and Renal Function. Role as Predictive Renal Injury Biomarkers.

Authors:  Félix Vargas; Rosemary Wangesteen; Isabel Rodríguez-Gómez; Joaquín García-Estañ
Journal:  Int J Mol Sci       Date:  2020-08-05       Impact factor: 5.923

Review 4.  Aminopeptidase N in arterial hypertension.

Authors:  Robert S Danziger
Journal:  Heart Fail Rev       Date:  2007-11-16       Impact factor: 4.214

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.